White Willow Bark Extract

White Willow Bark Extract

Main Active Ingredient:
Salicin — CAS: 138-52-3 | Assay: 15% / 25% / up to 95% Salicin (HPLC) | Salix alba L. Bark (White Willow Bark)
Application: joint health & mobility supplements | sports recovery formulations | anti-inflammatory blends | topical gels & cosmeceutical formulations | headache & pain management formulas | nutraceutical ingredient applications
Ratio Extracts — 4:1 / 10:1 / 20:1
MOQ: 1KG (Batch-specific HPLC Salicin % and residual solvent testing documentation available)
Certifications: FDA Registered Facility, GMP, ISO, Kosher, Halal, Non-GMO

Send Inquiry

Thank you for sharing our article through the button

Facebook
X
LinkedIn
Telegram
Reddit

Bulk White Willow Bark Extract Supplier — Salix alba: Salicin 15%–95% HPLC & 4:1 / 10:1 / 20:1 Ratio Extracts, B2B Wholesale

Written by Jonathan, Valeherb · Reviewed by Dr. Xiaoyan Qiu · Updated June 2026

Valeherb supplies white willow bark extract bulk wholesale — Salix alba bark extract — across two product lines: standardized extracts (15%, 25%, up to 95% salicin by HPLC) and full-spectrum concentration-ratio extracts (4:1, 10:1, 20:1), with custom specifications available for joint health, sports recovery, and topical anti-inflammatory formulation. Derived from the bark of Salix alba L. and related Salix species, white willow bark extract is one of the most extensively documented botanical analgesic ingredients in the European phytomedicine literature, with Commission E approval, an EMA well-established use monograph, and published RCT evidence for pain management support.[2] Salicin — the primary active precursor compound — is converted in vivo to salicylic acid via colonic bacterial action and hepatic metabolism, producing a gradual-release salicylate profile.

On this page: available grades, salicin mechanism and the multi-component advantage, white willow vs aspirin comparison, research background, formulation applications, sourcing criteria, and regulatory guidance.

Available Grades and Specifications

Standardized Extracts — Guaranteed Salicin Content

Grade Salicin Content Typical Application
Standard 15% salicin (HPLC) Entry-level joint health and pain support supplements; traditional herbal formulas
Mid-Potency 25% salicin (HPLC) Mainstream joint and sports recovery capsules; the most common commercial specification
High-Potency Up to 95% salicin (HPLC) Clinical-grade pain management formulas; low-dose capsule applications; EU herbal medicinal product positioning

Ratio Extracts — 4:1 / 10:1 / 20:1

Full-spectrum whole-bark extracts that retain the native polyphenol/flavonoid fraction alongside salicin. The ratio describes how much raw bark is concentrated into the finished extract. Salicin content is reported as-tested per batch rather than guaranteed to a fixed level.

Grade (Ratio) Concentration Profile Typical Application
4:1 Full-spectrum — salicin + polyphenols, entry concentration Traditional herbal formulas, full-spectrum botanical positioning
10:1 Concentrated full-spectrum Mainstream joint and sports-recovery blends; multi-mechanism pain formulas
20:1 High-concentration full-spectrum Premium full-spectrum formulations; compact dosing

Custom salicin levels, custom ratios, and extracts specified to a minimum total-polyphenol content produced on request. MOQ, lead time, and current pricing available on inquiry.

Mechanism: Salicin and the Multi-Component Advantage

White willow bark extract’s pharmacological profile is driven by salicin but is not reducible to it. Salicin is hydrolysed in the colon by bacterial esterases, then oxidised in the liver to salicylic acid — the analgesic metabolite. Because this conversion is gradual, peak plasma salicylate levels are lower and slower than those produced by direct oral salicylate administration.

The bark’s polyphenol and flavonoid fraction — catechins, epicatechin, and flavone glycosides — modulates COX-2 mRNA expression independently of salicylate pathways, contributing to the overall analgesic profile beyond what salicin content alone predicts.[2]

SOURCING NOTE
The most common specification gap in white willow bark procurement is requesting “white willow bark extract 15% salicin” without specifying the polyphenol fraction. The published clinical evidence — including the Chrubasik back pain RCT — used standardised whole-bark extract, not isolated salicin. This is why the ratio extracts (4:1 / 10:1 / 20:1) are full-spectrum: they retain the polyphenol fraction that the clinical studies actually evaluated. For standardized salicin grades, specifying a minimum total polyphenol content alongside the salicin percentage better reflects the whole-bark extract profile used in the published trials.

White Willow vs. Aspirin: Key Distinctions for Label Positioning

Factor Synthetic Aspirin (ASA) White Willow Bark Extract
Active Compound Acetylsalicylic acid (ASA) Salicin → salicylic acid (via metabolism)
Onset Profile Rapid peak — sharp salicylate spike Gradual conversion — sustained salicylate release
Antiplatelet Activity Strong, irreversible platelet inhibition Weaker antiplatelet effect — different clinical risk profile
Regulatory Status OTC drug (US, EU) Dietary supplement (US DSHEA); herbal medicinal product (EU)
Label Claim Pathway Drug claim — NDA required Structure/function claim (US); EMA well-established use (EU)

Research Background

The activity described below is reported in published research. It is provided as scientific context for formulators, not as claims for any Valeherb product.

1. Back Pain — Placebo-Controlled RCT

The pivotal clinical reference is a randomised, double-blind, placebo-controlled trial by Chrubasik et al. (2000, American Journal of Medicine) enrolling 210 patients with chronic lower back pain exacerbations. Subjects receiving standardised Salix extract at a dose delivering 240 mg salicin per day showed a 39% response rate (clinically significant pain reduction) after four weeks, compared to 6% in the placebo group — a statistically and clinically significant difference in this trial.[2] This study is the primary evidence base cited in the EMA HMPC monograph and Commission E approval.

2. Willow Bark vs COX-2 Inhibitor — Randomized Controlled Study

Chrubasik et al. (2001, Rheumatology) conducted a randomized, open-label, controlled study comparing willow bark extract (240 mg salicin daily) with rofecoxib (12.5 mg daily) in 228 patients with acute exacerbations of chronic low back pain over four weeks. The study reported comparable pain reduction outcomes between the two groups.[3] These findings are reported here as research context; analgesic drug comparisons are not permissible claims for dietary supplement or herbal product labelling.

Formulation Applications

  • Joint health and mobility supplements: 25% standardized or 10:1 ratio extract at 400–800 mg per serving (delivering ~100–200 mg salicin). Pairs with boswellia serrata, turmeric extract, and glucosamine in comprehensive joint support stacks
  • Sports recovery formulations: Standardised or full-spectrum ratio extract for post-exercise support. Clean-label botanical option for sports recovery products seeking salicylate-pathway activity without synthetic analgesic positioning
  • Topical formulations: White willow bark extract provides a botanical source of salicylate activity for topical gels and cosmeceutical formulations. Natural salicylate-derived ingredient for skin-care positioning — note that topical cosmetic claims must comply with the cosmetic regulations of the relevant market，see our Willow Bark Extract for Skin: Salicin in Cosmetic Formulation
  • Headache and pain management blends: Combines with feverfew (Tanacetum parthenium) and ginger extract for multi-mechanism headache and migraine support formulations

Sourcing Criteria

Criterion What to Require
Salicin Content HPLC-verified salicin to the specified level (15% / 25% / up to 95%) per batch for standardized grades. For ratio grades, salicin reported as-tested. Colorimetric methods are less accurate — request HPLC method confirmation
Total Polyphenol Content For full-spectrum clinical positioning: request total polyphenol content alongside salicin — this better reflects the whole-bark extract profile used in published RCTs, and is naturally retained in the ratio (full-spectrum) line
Species Specification Salix alba (white willow) is the primary clinical species. Salix daphnoides and Salix purpurea are also accepted in the EMA monograph — confirm which species or mixture is supplied on the COA
COA & Compliance Per-batch COA: salicin (HPLC), heavy metals (USP <232>), pesticide residues, microbial limits (USP <2021>), moisture. EMA/HMPC/181727/2007 alignment for EU; Non-GMO / Kosher / Halal and FDA-registered facility on request
CAUTION
Aspirin/salicylate hypersensitivity — most important safety disclosure: White willow bark extract produces salicylate metabolites and is contraindicated in individuals with aspirin or salicylate hypersensitivity — this cross-reactivity must be clearly disclosed on consumer product labels. Higher-strength grades (95% salicin, or 20:1 ratio) concentrate the salicylate load; per-gram dosing must be adjusted to the target salicin amount, not fixed extract weight. Anticoagulant interaction: salicylates have antiplatelet activity — precautionary disclosure for warfarin, heparin, and anticoagulant medication users. Not recommended during pregnancy — salicylates are associated with adverse fetal outcomes at high doses; standard supplement doses have insufficient safety data in pregnancy. Not recommended for children under 18 due to Reye’s syndrome risk associated with salicylate use in febrile illness. Renal disease: salicylates are renally excreted — caution in individuals with impaired kidney function. Mild GI discomfort reported at higher doses; manageable with food co-administration.

Regulatory Guidance

  • EU (EMA/HMPC): White willow bark holds a well-established use monograph (EMA/HMPC/181727/2007) for temporary relief of lower back pain and minor joint pain — one of the strongest EMA endorsements for a botanical analgesic ingredient. Standardisation to salicin content required[4]
  • Germany (Commission E): Approved for diseases accompanied by fever, rheumatic ailments, and headaches — foundational phytomedicine approval predating the EMA monograph
  • US (DSHEA): Joint health, pain support, and anti-inflammatory structure/function claims supportable with published RCT data — each must be self-substantiated by the marketer and carry the required FDA disclaimer. Pain treatment claims (e.g., “treats pain”) are drug claims requiring NDA. “Supports healthy inflammatory response” and “joint comfort” are appropriate structure/function framings
  • Canada (NHPs): White willow bark has a licensed Health Canada monograph supporting analgesic and anti-inflammatory claims under Natural Health Products Regulations

References

[1] Mahdi JG, Mahdi AJ, Mahdi AJ, Bowen ID. (2006). The historical analysis of aspirin discovery, its relation to the willow tree and antiproliferative and anticancer potential. Cell Proliferation. 2006;39(2):147-155. doi: 10.1111/j.1365-2184.2006.00377.x

[2] Chrubasik S, Eisenberg E, Balan E, Weinberger T, Luzzati R, Conradt C. (2000). Treatment of low back pain exacerbations with willow bark extract: a randomized double-blind study. American Journal of Medicine. 2000;109(1):9-14. doi: 10.1016/S0002-9343(00)00442-3

[3] Chrubasik S, Künzel O, Model A, Conradt C, Black A. (2001). Treatment of low back pain with a herbal or synthetic anti-rheumatic: a randomized controlled study. Willow bark extract for low back pain. Rheumatology (Oxford). 2001;40(12):1388-1393. doi: 10.1093/rheumatology/40.12.1388

[4] European Medicines Agency. (2009). Assessment report on Salix [various species], cortex. EMA/HMPC/181727/2007.

Reviewed byDr. Xiaoyan QiuBotanical Extract R&D Engineer · Associate Professor, Huaihua University. Research focus: medicinal plant resources, botanical extraction processes, and microbial fermentation technology.
Written byJonathanContent Editor, Valeherb. Specializing in botanical ingredient science communication for B2B nutraceutical and functional food markets.

Disclaimer: This article is intended for informational purposes only. All health-related statements reference published peer-reviewed research and are not intended as medical advice. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Products must comply with applicable regulations in the buyer’s jurisdiction. © 2026 Valeherb. All rights reserved.

FAQ

A1:The percentage reflects HPLC-verified salicin content per gram of extract. The 15% grade is the entry specification for traditional herbal formula blends and broad-spectrum joint formulas where cost efficiency matters. The 25% grade is the most common commercial specification for joint health and sports recovery capsules — it delivers approximately 50–60 mg salicin per 200–250 mg serving, which is within the range used in published clinical studies. The 95% grade allows for a more compact capsule format at equivalent salicin doses and is the appropriate specification for EU herbal medicinal product positioning aligned with the EMA monograph.
A2:Published pharmacological research on willow bark extract indicates that the polyphenol and flavonoid fraction — catechins, epicatechin, and flavone glycosides — contributes to the overall analgesic profile through COX-2 mRNA modulation independently of the salicylate pathway. The clinical RCTs that established willow bark’s evidence base, including the Chrubasik 2000 back pain study, all used standardised whole-bark extracts, not isolated salicin. This is why the ratio extracts (4:1 / 10:1 / 20:1) retain the native polyphenol fraction. For the most clinically relevant positioning, specifying a minimum total polyphenol content alongside the salicin percentage is recommended.
A3:Four disclosures are non-negotiable for consumer-facing labelling. First, salicylate hypersensitivity: white willow bark extract produces salicylate metabolites and is contraindicated in aspirin or salicylate-sensitive individuals — cross-reactivity is real and must be disclosed. Second, Reye’s syndrome risk: not recommended for anyone under 18 years of age, consistent with standard salicylate safety guidance. Third, anticoagulant interaction: salicylates have antiplatelet activity — users on warfarin, heparin, or anticoagulants require precautionary disclosure. Fourth, pregnancy: not recommended due to the association of salicylates with adverse fetal outcomes at high doses and insufficient pregnancy safety data for extract doses. Renal disease also warrants a caution since salicylates are renally excreted.
A4:From a regulatory standpoint, white willow bark extract in the US is a dietary supplement under DSHEA, not an OTC drug. This means analgesic structure/function claims (e.g., “supports healthy inflammatory response,” “joint comfort support”) are permissible with self-substantiation and the required FDA disclaimer, but pain treatment or disease claims require drug approval. In the EU, white willow bark has an EMA well-established use monograph for temporary relief of lower back pain and minor joint pain — one of the strongest evidence bases for any botanical analgesic ingredient — but EU-positioned products must follow the herbal medicinal product regulatory pathway, not the food supplement route, if making this claim. Direct drug comparisons are not permissible on supplement labelling in any market.

Related products

SEND INQUIRY

Contact Form Demo
Mogroside V: Grades, Stability and Performance Guide

The essence of natural sweetness — extracted directly from plants

monk fruit extract-mogroside V
Trilobatin Inclusion Rate and Blend Systems

The most promising sugar-free and zero-calorie sweetener usage guide for 2026

Trilobatin Inclusion Rate
The 7 Best Zero-Calorie Sweeteners

Understand the gap between natural sweeteners and synthetic sweeteners

Zero-Calorie Sweeteners